Detailed Narrative
Q4 and Full Year FY25 Financial Performance
Emami reported a consolidated revenue of ₹963 crores for Q4 FY25, marking an 8% year-on-year increase. For the full fiscal year, consolidated revenue reached ₹3,809 crores, growing by 6.5%. Gross margins expanded by 10 basis points to 65.9% in Q4 and by 100 basis points to 68.6% for the full year. EBITDA for Q4 stood at ₹219 crores (+4% YoY), while full-year EBITDA grew 8% to ₹1,025 crores, with margins improving by 40 basis points to 26.9%. Profit after tax for Q4 was ₹162 crores (+9% YoY) and ₹806 crores (+11% YoY) for the full year.
Domestic Business and Category Performance
The core domestic business demonstrated robust growth, increasing by 11% in Q4 FY25 with a 7% volume growth. Key categories like Navratna and Dermicool grew by 16%, BoroPlus by 27%, and Healthcare by 13%. The newly rebranded Smart and Handsome achieved 7% growth, while Kesh King experienced flattish growth and pain management grew by 1%. Overall domestic business grew 9% in Q4 (5% volume growth) after absorbing a 12% decline from the strategic investment portfolio. For FY25, domestic business grew 7%, with organized channels growing 13% and contributing 28% to domestic revenue.
Strategic Investments and New Initiatives
Emami is actively addressing challenges in Kesh King and The Man Company, with a BCG-developed strategy for Kesh King set for Q2 FY26 rollout. The Man Company saw the appointment of Mr. Zairus Master as CEO/Director, tasked with driving growth and profitability. The D2C platform, Zanducare, grew over 50% year-on-year in FY25, with products launched in the last two years contributing 50% to its total sales. The company also launched Emami Pure Glow in the brightening skincare category and plans two new pain management products in FY26.
International Business Performance
Despite geopolitical and macroeconomic challenges in regions like Bangladesh, the Middle East, and parts of Africa, the international business returned to growth in Q4 FY25, posting a 6% increase. This segment now contributes approximately 20% to the company's total revenue. Performance was strong in SAARC, Southeast Asia, CIS, and other African regions, with Bangladesh showing significant improvement.
Shareholder Returns and Capital Allocation
The Board of Directors approved a special interim dividend of 200% (₹2 per equity share) for Q4 FY25. Including previous interim dividends of 400% each (₹4 per share) in Q2 and Q3, the total dividend payout for FY25 stands at 1000% (₹10 per share). This represents a payout ratio of 49% on adjusted PAT, aligning with the company's dividend policy and commitment to maximizing shareholder value.
Outlook and Key Growth Drivers for FY26
Emami is optimistic about delivering robust all-round growth in FY26, anticipating a gradual pickup in consumption driven by easing inflation and government initiatives. The company expects high double-digit growth from Brillare and The Man Company, 5-6% growth from Healthcare, and 2-3% pricing growth. New product launches are projected to contribute around 3% to revenue. Strategic actions in male grooming and Kesh King are expected to build positive momentum, with several new launches planned for Q2 FY26.
Market and Seasonal Challenges
Consumption demand trends in Q4 remained similar to the previous quarter, with rural markets performing well but mass urban demand remaining subdued. The summer portfolio, particularly talc, is facing a 'slight dent' in Q1 FY26 due to unseasonal rainfalls across India and a high base from the previous year. Management acknowledged these challenges but expressed confidence in mitigating their impact through other portfolio strengths and disciplined trade loading.